Literature DB >> 12833648

Antisense oligonucleotides to Syk kinase: a novel therapeutic approach for respiratory disorders.

Marina Ulanova1, Lakshmi Puttagunta, Moo-Kyung Kim, Alan D Schreiber, A Dean Befus.   

Abstract

The non-receptor protein tyrosine kinase Syk plays a critical role in intracellular signaling in the inflammatory response. Specific inhibition of Syk using aerosolized antisense delivered in liposome complexes can significantly decrease inflammatory responses in the airways in experimental animal models. Thus, it is tempting to examine local application of Syk antisense for the treatment of inflammatory respiratory diseases as asthma. However, evidence that Syk kinase is more widely distributed in different cell types than previously recognized, as well as its potential involvement in cell differentiation, adhesion and proliferation, dictates that the precise cellular targets for antisense therapy in the airways must be determined. Given the critical role of Syk in intracellular signaling in inflammatory responses, Syk antisense oligonucleotides (InKine Pharmaceutical Co Inc) may prove useful as anti-inflammatory therapy in disorders such as asthma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12833648

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN: 1472-4472


  3 in total

1.  Differential expression of spleen tyrosine kinase Syk isoforms in tissues: Effects of the microbial flora.

Authors:  Florentina Duta; Marina Ulanova; Daniel Seidel; Lakshmi Puttagunta; Sorin Musat-Marcu; Kevin S Harrod; Alan D Schreiber; Ulrich Steinhoff; A Dean Befus
Journal:  Histochem Cell Biol       Date:  2006-05-18       Impact factor: 4.304

2.  A review of antisense therapeutic interventions for molecular biological targets in asthma.

Authors:  Florin-Dan Popescu; Florica Popescu
Journal:  Biologics       Date:  2007-09

3.  Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcepsilonRI-activated RBL-2H3 basophilic cells.

Authors:  Michael P Sanderson; Stephen J Gelling; Jörg F Rippmann; Andreas Schnapp
Journal:  Cell Immunol       Date:  2009-12-14       Impact factor: 4.868

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.